Compare SCNI & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCNI | JAGX |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 3.9M |
| IPO Year | N/A | N/A |
| Metric | SCNI | JAGX |
|---|---|---|
| Price | $0.94 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 41.7K | ★ 380.3K |
| Earning Date | 11-24-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | $1,147,000.00 | ★ $11,785,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | $4.55 | ★ N/A |
| Revenue Growth | ★ 303.87 | 12.45 |
| 52 Week Low | $0.86 | $1.00 |
| 52 Week High | $6.18 | $33.25 |
| Indicator | SCNI | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 41.39 |
| Support Level | $1.14 | $1.05 |
| Resistance Level | $1.26 | $1.36 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 13.13 | 38.00 |
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.